2024年美国临床肿瘤学会（ASCO）年会将于当地时间2024年5月31日至6月4日在美国芝加哥盛大召开。作为肿瘤领域最具权威性的年度盛会，全球肿瘤学领域的多项重磅研究将于此次大会公布结果。现在2024年ASCO会议的讨论题目已经公开，黑色素瘤的研究有哪些？【肿瘤资讯】整理如下，以飨读者
口头摘要专场
摘要号：5502
Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study.
Vibostolimab联合帕博利珠单抗（vibo/pembro）治疗既往接受过治疗的晚期错配修复缺陷（dMMR）子宫内膜癌：来自KEYVIBE-005 II期研究B1队列的结果
讲者：Carlos Rojas，Bradford Hill Clinical Research Center
摘要号：5503
Trends in phase 3 gynecological clinical trials of targeted therapies: Study oversight and pharmaceutical involvement in the past 12 years.
妇科领域靶向治疗3期临床试验的趋势：对过去12年的研究监控和制药参与
讲者：Qiao Ruan，California Pacific Medical Center
摘要号：5504
Adjuvant chemotherapy following concurrent chemoradiation (CRT) in patients with high-risk early-stage cervical carcinoma following radical hysterectomy: Results of NRG oncology/RTOG 0724/GOG-0724.
高危早期宫颈癌根治性子宫切除术后同步放化疗（CRT）后的辅助化疗：NRG肿瘤学/RTOG 0724/GOG-0724的结果
讲者：Anuja Jhingran，The University of Texas MD Anderson Cancer Center
摘要号：5506
Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial.
奥拉帕利新辅助治疗铂敏感复发性高级别浆液性卵巢癌患者的 II 期随机多中心研究：NEO 试验
讲者：Stephanie Lheureux，Princess Margaret, University Health Network
摘要号：5507
Endometrial cancer and obesity trends in the United States in the 21st century.
21 世纪美国子宫内膜癌和肥胖趋势
讲者：Alex Francoeur，UC Irvine Health
摘要号：5508
Long-term survival outcomes for hormonal therapy in premenopausal patients with clinical stage I endometrial cancer.
临床 I 期子宫内膜癌绝经前患者激素治疗的长期生存结果
讲者：Yukio Suzuki，Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons
LBA
摘要号：LBA5500
Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas.
BrUOG 354的最终结果：纳武利尤单抗单独或与伊匹单抗联合治疗卵巢癌和其他肾外透明细胞癌患者的随机II期试验
讲者：Don Dizon，Lifespan Cancer Institute, Rhode Island Hospital
摘要号：LBA5501
Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.
阿替利珠单抗与安慰剂联合贝伐珠单抗和非铂类化疗治疗复发性卵巢癌：AGO-OVAR 2.29/ENGOT-ov34 研究的最终总体生存期和无进展生存期结果
讲者：Frederik Marmé，Heidelberg University, University Hospital Mannheim
摘要号：LBA5505
Omission of lymphadenectomy in patients with advanced epithelial ovarian cancer treated with primary or interval cytoreductive surgery after neoadjuvant chemotherapy: The CARACO phase III randomized trial.
晚期上皮性卵巢癌患者在新辅助化疗后接受原发性或间歇性肿瘤细胞减灭术治疗时省略淋巴结切除术：CARACO III期随机试验
讲者：Jean-Marc Classe，Nantes Université
摘要号：LBA5515
AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer.
AXLerate-OC/GOG-3059/ENGOT OV-66：一项batiraxcept （AVB-S6-500）联合紫杉醇治疗铂类耐药复发性卵巢癌患者的III期、随机、双盲、安慰剂/紫杉醇对照研究的结果。
讲者：Katherine Fuh，University of California, San Francisco
摘要号：LBA5516
A phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer (SCORES).
一项苏维西塔单抗（suvemcitug，曾用名：赛伐珠单抗）联合化疗治疗铂类耐药卵巢癌的III期、随机、双盲、安慰剂对照研究（SCORES）
讲者：袁光文，国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院肿瘤研究所
临床科学研讨会
摘要号：5509
A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort.
TORC1/2抑制剂onatasertib联合torpalimab用于晚期实体瘤患者的1/2期研究：宫颈癌队列
讲者：谢辉，德琪医药
摘要号：5510
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A).
ATR 和 PARP 抑制剂联合用药 (CAPRI)：一项 ceralasertib 加奥拉帕利治疗复发性铂敏感上皮性卵巢癌患者的 2 期研究（队列A）
讲者：Fiona Simpkins，Penn Medicine Abramson Cancer Center
摘要号：5511
A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer.
氟维司群和阿贝西利治疗激素受体阳性晚期或复发性子宫内膜癌的II期研究
讲者：Angela Green，Memorial Sloan Kettering Cancer Center
快速摘要专场
摘要号：5512
Efficacy and safety of sintilimab plus paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer: A phase II trial.
信迪利单抗联合紫杉醇和顺铂作为局部晚期宫颈癌新辅助治疗的有效性和安全性：一项 II 期试验
讲者：刘继红，中山大学附属肿瘤医院妇科、华南肿瘤学国家重点实验室、肿瘤医学协同创新中心
摘要号：5513
An open label, single arm phase II, multicenter trial of durvalumab and BVAC-C, in patients with HPV 16- or 18-positive cervical cancer and failure of first-line platinum-based chemotherapy (DURBAC).
一项在HPV 16或18阳性，且一线铂类化疗失败的宫颈癌患者中评价度伐利尤单抗和BVAC-C的开放标签、单臂、II期、多中心试验（DURBAC）
讲者：Chel Hun Choi，Department of Obstetrics and Gynecology, Samsung Medical Center
摘要号：5514
Nimotuzumab plus concurrent chemoradiotherapy for locally advanced cervical squamous cell carcinoma: The randomized, phase 3 CC3 study.
尼妥珠单抗联合同步放化疗治疗局部晚期宫颈鳞状细胞癌：随机、3期CC3研究
讲者：王俊杰，北京大学第三医院[MOU4]
摘要号：5517
Oral cyclophosphamide plus bevacizumab in recurrent ovarian, fallopian tube and primary peritoneal cancer.
口服环磷酰胺加贝伐珠单抗治疗复发性卵巢癌、输卵管癌和原发性腹膜癌
讲者：Mostafa Eyada，University of Texas Medical Branch
摘要号：5518
Relationship of cancer stem cell functional assay and objective response rate of patients with recurrent platinum-resistant ovarian cancer in a randomized trial.
随机试验中癌症干细胞功能测定与复发性铂耐药卵巢癌患者客观缓解率的关系
讲者：Thomas Herzog，University of Cincinnati
摘要号：5519
Optimization of intra-peritoneal chemotherapy: Randomized phase II GERCOR CHIMOVIP study.
腹腔内化疗的优化：随机 II 期 GERCOR CHIMOVIP 研究
讲者：Romain Cohen，Sorbonne University, Department of Medical Oncology, Saint-Antoine Hospital, AP-HP
摘要号：5520
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): A final overall survival analysis of a multicenter, open-label, randomized, phase 3 trial.
铂敏感复发性卵巢癌中二次细胞减灭术后化疗与单纯化疗的比较 (SOC-1) ：多中心、开放标签、随机、3 期试验的最终总体生存分析
讲者：臧荣余，复旦大学附属中山医院妇科肿瘤科
排版编辑：肿瘤资讯-Annie
苏公网安备32059002004080号
